We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you accept our Privacy Policy and Terms of Service, revised from time to time, and you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sage Therapeutics (SAGE) Moves 35.1% Higher: Will This Strength Last?
Read MoreHide Full Article
Sage Therapeutics, Inc. (SAGE - Free Report) shares soared 35.1% in the last trading session to close at $7.50. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 3.1% gain over the past four weeks.
The stock rallied after the company announced that its partner Biogen had made an unsolicited, non-binding proposal offer to acquire SAGE shares that it does not already own for $7.22 per share. The offer price represented a premium of 30% on Sage Therapeutics’ closing price of $5.55 on Jan 10.
This company is expected to post quarterly loss of $1.44 per share in its upcoming report, which represents a year-over-year change of -161.8%. Revenues are expected to be $13.96 million, down 82.1% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Sage Therapeutics, the consensus EPS estimate for the quarter has been revised 2.1% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on SAGE going forward to see if this recent jump can turn into more strength down the road.
Sage Therapeutics belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Zai Lab Limited Unsponsored ADR (ZLAB - Free Report) , closed the last trading session 0.4% lower at $25.21. Over the past month, ZLAB has returned -3.9%.
For Zai Lab Limited, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.67. This represents a change of +31.6% from what the company reported a year ago. Zai Lab Limited currently has a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Sage Therapeutics (SAGE) Moves 35.1% Higher: Will This Strength Last?
Sage Therapeutics, Inc. (SAGE - Free Report) shares soared 35.1% in the last trading session to close at $7.50. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 3.1% gain over the past four weeks.
The stock rallied after the company announced that its partner Biogen had made an unsolicited, non-binding proposal offer to acquire SAGE shares that it does not already own for $7.22 per share. The offer price represented a premium of 30% on Sage Therapeutics’ closing price of $5.55 on Jan 10.
This company is expected to post quarterly loss of $1.44 per share in its upcoming report, which represents a year-over-year change of -161.8%. Revenues are expected to be $13.96 million, down 82.1% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Sage Therapeutics, the consensus EPS estimate for the quarter has been revised 2.1% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on SAGE going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Sage Therapeutics belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Zai Lab Limited Unsponsored ADR (ZLAB - Free Report) , closed the last trading session 0.4% lower at $25.21. Over the past month, ZLAB has returned -3.9%.
For Zai Lab Limited, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.67. This represents a change of +31.6% from what the company reported a year ago. Zai Lab Limited currently has a Zacks Rank of #3 (Hold).